LicianPro

Travere Therapeutics, Inc. ·

TVTX 8-K 2026-09-21

Travere Therapeutics, Inc. (TVTX) 8-K dated 2026-09-21 — accession 0001438533-26-000068.

Travere Therapeutics, Inc. (TVTX) is a biotechnology company listed on US.

Travere Therapeutics, Inc. filed a 8-K on 2026-09-21. Accession 0001438533-26-000068.

This 8-K covers: Director/officer change (Item 5.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported TVTX revenue for 2025-12-31 was $490.7M. Net income was -$25.5M. Revenue was up 110.5% from 2024-12-31 to 2025-12-31. TVTX currently screens at market cap $1.33B.

Not investment advice. The TVTX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr